BioNTech SE (NASDAQ:BNTX) Shares Acquired by Flossbach Von Storch SE

Flossbach Von Storch SE lifted its position in shares of BioNTech SE (NASDAQ:BNTX) by 1.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,406,843 shares of the company’s stock after buying an additional 47,236 shares during the period. BioNTech makes up approximately 2.0% of Flossbach Von Storch SE’s portfolio, making the stock its 20th largest position. Flossbach Von Storch SE’s holdings in BioNTech were worth $502,160,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Fred Alger Management LLC acquired a new stake in BioNTech in the 3rd quarter valued at approximately $59,485,000. Baillie Gifford & Co. lifted its position in shares of BioNTech by 0.4% during the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock worth $986,750,000 after purchasing an additional 31,773 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in BioNTech by 63.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock valued at $2,249,000 after acquiring an additional 7,340 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in BioNTech by 123.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock valued at $15,919,000 after acquiring an additional 74,119 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in BioNTech by 412.3% in the fourth quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock valued at $4,726,000 after acquiring an additional 33,375 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. BMO Capital Markets restated an “outperform” rating on shares of BioNTech in a research note on Monday, December 2nd. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $90.00 to $137.00 in a research note on Friday, November 8th. HC Wainwright restated a “buy” rating and issued a $150.00 price objective on shares of BioNTech in a research note on Monday, November 18th. Evercore ISI upgraded shares of BioNTech from an “in-line” rating to an “outperform” rating and boosted their price target for the stock from $110.00 to $125.00 in a research note on Tuesday, November 19th. Finally, Berenberg Bank began coverage on shares of BioNTech in a research note on Tuesday, November 19th. They set a “buy” rating and a $130.00 price target on the stock. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $142.72.

BioNTech Trading Down 2.6 %

Shares of BNTX opened at $119.58 on Thursday. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm’s 50-day moving average is $117.33 and its two-hundred day moving average is $110.25. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49. The firm has a market capitalization of $28.67 billion, a P/E ratio of -56.94 and a beta of 0.17.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.